Mauro Schechter

Mauro Schechter

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2004 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Closed access
MSMauro Schechter
Mauro Schechter
RLRegina F. Do Lago
Regina F. Do Lago
AMAaron B. Mendelsohn
Aaron B. Mendelsohn
RMRonaldo I. Moreira
Ronaldo I. Moreira
LMLawrence H. Moulton
Lawrence H. Moulton
LHLee H. Harrison
Lee H. Harrison
Little is known about the behavioral impact, acceptability, and incidence of HIV infection in persons with easy access to post–sexual exposure prophylaxis (PEP) to prevent HIV. Participants were recruited from a well-characterized, high-risk HIV seronegative homosexual male cohort in Rio de Janeiro, Brazil, given a 4-day supply of zidovudine and lamivudine, and instructed to begin PEP immediately after an eligible exposure. For eligible exposures, an additional 24-day supply was provided. Reported behavior, PEP utilization, adverse events, and incident HIV infection were the main study outcomes. The observed and expected incidences of HIV infection were compared. Two hundred subjects were enrolled and followed for a median of 24.2 months. The median age was 28 years. PEP was initiated 109 times by 68 participants (34.0%). In comparison to reported behavior at baseline, reported high-risk sexual activities on average declined over time for both PEP and non-PEP users. There were no serious drug-related adverse events. There were 11 HIV seroconversions, 10 among non-PEP users and 1 that was a PEP failure. The overall seroincidence was 2.9 per 100 person-years (95% CI = 1.4, 5.1). The expected number of new HIV infections and corresponding expected seroincidence based on the risk profile were 11.8 and 3.1, respectively (P > 0.97). The most commonly reported reasons for not initiating PEP among seroconverters were sex with a steady partner and not considering the exposure to be of sufficiently high risk to warrant PEP. PEP was safe and did not appear to be associated with increases in reported high-risk behavior in our cohort. Ready access to PEP did not appear to substantially affect HIV transmission, suggesting a limited public health impact of this intervention.

15 February 2002 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
GSGuilherme Santoro-Lopes
Guilherme Santoro-Lopes
APAna Maria Felix de Pinho
Ana Maria Felix de Pinho
LHLee H. Harrison
Lee H. Harrison
MSMauro Schechter
Mauro Schechter
This observational study assessed the effect of combination antiretroviral therapy on the risk of tuberculosis among 255 patients with human immunode

1 December 2009 in HIV Research & Clinical Practice
Verified
Journal Article
Closed access
ENEstevão P. Nunes
Estevão P. Nunes
MOMarilia Santini de Oliveira
Marilia Santini de Oliveira
MMMonica Merçon
Monica Merçon
RZRoberto Zajdenverg
Roberto Zajdenverg
JFJose Claudio Faulhaber
Jose Claudio Faulhaber
MSMauro Schechter
Mauro Schechter
Long-term adverse events and expenses associated with HAART have led to an interest in simplified therapy. Lopinavir/ritonavir monotherapy is attractive due to its potency and high genetic barrier. This is a 96-week, open-label, randomized study to assess the feasibility of using LPV/r monotherapy in patients with undetectable viral load after being on successful HAART for at least 6 months. Subjects were randomized (1:1) to either switch from HAART to LPV/r monotherapy or to maintain their previous regimen. 60 patients were enrolled. Baseline characteristics were similar in both groups. At Week 96, by intention-to-treat analysis, 24/30 (80.0%) subjects in monotherapy group and 26/30(86.6%) in the control group had a plasma viral load of <80 copies/mL. There was one virologic failure (defined as VL not greater-than 500 copies/mL) in each arm. Genotyping testing identified no resistance-associated mutations. The patient on the monotherapy arm was successfully resuppressed to <80 copies/mL after intensification with tenofovir and lamivudine. No statistically significant differences were found with regard to changes in CD4 counts. One subject in the monotherapy group discontinued due to diarrhea. Five subjects in the control group underwent regimen changes due to drug-related toxicities. Viral load from semen samples collected at the end of follow-up was undetectable on 14/15 patients randomized to monotherapy. Switching from various HAART regimens to LPV/r monotherapy in patients who were virologically suppressed and without a history of previous virologic failure was effective, safe, and well tolerated through 96 weeks.

1 January 2010 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Closed access
STSuely Hiromi Tuboi
Suely Hiromi Tuboi
APAntonio Guilherme Pacheco
Antonio Guilherme Pacheco
LHLee H Harrison
Lee H Harrison
RSRoslyn A Stone
Roslyn A Stone
MMMargaret May
Margaret May
MSMauro Schechter
Mauro Schechter
Objectives: We assessed mortality associated with immunologic and virologic patterns of response at 6 months of highly active antiretroviral therapy (HAART) in HIV-infected individuals from resource-limited countries in Africa and South America. Methods: Patients who initiated HAART between 1996 and 2007, aged 16 years or older, and had at least 1 measurement (HIV-1 RNA plasma viral load or CD4 cell count) at 6 months of therapy (3-9 month window) were included. Therapy response was categorized as complete, discordant (virologic only or immunologic only), and absent. Associations between 6-month response to therapy and all-cause mortality were assessed by Cox proportional hazards regression. Robust standard errors were calculated to account for intrasite correlation. Results: A total of 7160 patients, corresponding to 15,107 person-years, were analyzed. In multivariable analysis adjusted for age at HAART initiation, baseline clinical stage and CD4 cell count, year of HAART initiation, clinic, occurrence of an AIDS-defining condition within the first 6 months of treatment, and discordant and absent responses were associated with increased risk of death. Conclusions: Similar to reports from high-income countries, discordant immunologic and virologic responses were associated with intermediate risk of death compared with complete and no response in this large cohort of HIV-1 patients from resource-limited countries. Our results support a recommendation for wider availability of plasma viral load testing to monitor antiretroviral therapy in these settings.

1 July 2006 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
MSMauro Schechter
Mauro Schechter
STSuely Hiromi Tuboi
Suely Hiromi Tuboi
In response to antiretroviral therapy, some patients experience what has been termed a discordant response, characterized either by a sustained CD4+ cell count rise despite persistent viraemia or by HIV-1 RNA plasma levels below the limit of detection accompanied by a blunted CD4+ cell count response. In part because of a lack of universally accepted definitions, published estimates of the frequency of discordant responses vary considerably. Little is known about the pathogenesis of discordant responses, which seems to depend on the interaction of a multitude of viral, host and treatment-related factors. Available evidence indicates that discordant responses are associated with an intermediate risk of death or clinical progression. At present, recommendations for the clinical management of patients with discordant responses to antiretroviral therapy are largely based on observational, uncontrolled data. The development of standardized and universally accepted definitions of discordant responses is necessary to allow meaningful comparisons between studies to be made, as well as to help in the design of trials of possible therapeutic interventions.

1 June 2000 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Closed access
MSMauro Schechter
Mauro Schechter
RLRegina F. Do Lago
Regina F. Do Lago
MMMaria Fátima de Melo
Maria Fátima de Melo
HSHaynes W. Sheppard
Haynes W. Sheppard
NGNelson C. Guimarães
Nelson C. Guimarães
LHLee H. Harrison
Lee H. Harrison
Summary:The incidence of AIDS in French Guiana remains one of the highest in Latin America and the Caribbean. The annual AIDS incidence rate increased continually from the start of the epidemic until 1995, when it reached 59.3/100,000 population declining thereafter to 26.6 in 1997. The prevalence of HIV in pregnant women was 0.9% in 1993, increasing to 1.3% in 1995, and that in individuals attending sexually transmitted disease (STD) clinics was 2.1% in 1996. We included 224 patients in a study of survival after AIDS diagnosis. The principal AIDS-defining diagnosis was tuberculosis in 20.5% of reported cases. The median duration of survival was 10.2 months. Multivariate analysis showed that, patients ≥45 years at entry progressed more rapidly to AIDS than younger patients. HIV prevention and access to health care should be developed in the various ethnic communities and adapted to cultural status. The progressive implementation of multiple antiretroviral therapies since 1996 may further reduce progression of the disease but early HIV diagnosis is required to improve the overall prognosis of HIV-infected patients. Address correspondence and reprint requests to Milko Sobesky, CISIH, CHG de Cayenne, BP 6006, 97306, Cayenne, Guyane Française; email: [email protected] Manuscript received November 16, 1999; accepted February 29, 2000. © 2000 Lippincott Williams & Wilkins, Inc.